文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

长期使用质子泵抑制剂与幽门螺杆菌治疗后胃癌发生风险:一项基于人群的研究

Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study.
PubMed 文献 · Gut · 2017-10-31

该研究基于香港全港健康数据库,纳入2003至2012年间接受克拉霉素三联疗法的成人,分析质子泵抑制剂(PPI)使用与胃癌风险的关系。在中位随访7.6年的63 397例受试者中,153例(0.24%)发生胃癌;PPI使用与胃癌风险升高相关(HR 2.44,95%CI 1.42至4.20),而H2受体拮抗剂无此关联(HR 0.72,95%CI 0.48至1.07)。

要点

  • 在幽门螺杆菌治疗后的受试者中,PPI使用与胃癌风险升高相关(HR 2.44,95%CI 1.42至4.20)。
  • PPI使用时长与胃癌风险增加相关,≥1年、≥2年、≥3年的HR分别为5.04、6.65、8.34。
  • H2受体拮抗剂作为阴性对照暴露,未显示与胃癌风险显著相关(HR 0.72,95%CI 0.48至1.07)。

核心结论

  • 即使在幽门螺杆菌根除治疗后,长期使用PPI仍与胃癌风险升高相关。

研究设计与样本

  • 基于香港全港健康数据库的人群研究,纳入2003至2012年间接受克拉霉素三联疗法门诊处方的成人。
  • 排除克拉霉素三联疗法失败者、治疗后12个月内诊断胃癌者、治疗后胃溃疡者。
  • 排除胃癌诊断前6个月内开始的PPI或H2RA处方以避免原发病偏倚;采用倾向评分调整的Cox比例风险模型评估胃癌风险,H2RA作为阴性对照暴露。

主要发现

  • 63 397例合格受试者中,中位随访7.6年期间153例(0.24%)发生胃癌。
  • PPI使用与胃癌风险升高相关(HR 2.44,95%CI 1.42至4.20),H2RA使用与胃癌风险无显著关联(HR 0.72,95%CI 0.48至1.07)。
  • PPI使用时长与胃癌风险增加相关:≥1年HR 5.04(95%CI 1.23至20.61),≥2年HR 6.65(95%CI 1.62至27.26),≥3年HR 8.34(95%CI 2.02至34.41)。
  • PPI使用相对于非PPI使用的调整绝对风险差异为每10 000人年额外4.29例胃癌(95%CI 1.25至9.54)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Proton pump inhibitors (PPIs) is associated with worsening of gastric atrophy, particularly in Helicobacter pylori (HP)-infected subjects. We determined the association between PPIs use and gastric cancer (GC) among HP-infected subjects who had received HP therapy. DESIGNS: This study was based on a territory-wide health database of Hong Kong. We identified adults who had received an outpatient prescription of clarithromycin-based triple therapy between year 2003 and 2012. Patients who failed this regimen, and those diagnosed to have GC within 12 months after HP therapy, or gastric ulcer after therapy were excluded. Prescriptions of PPIs or histamine-2 receptor antagonists (H2RA) started within 6 months before GC were excluded to avoid protopathic bias. We evaluated GC risk with PPIs by Cox proportional hazards model with propensity score adjustment. H2RA was used as a negative control exposure. RESULT: Among the 63 397 eligible subjects, 153 (0.24%) developed GC during a median follow-up of 7.6 years. PPIs use was associated with an increased GC risk (HR 2.44, 95% CI 1.42 to 4.20), while H2RA was not (HR 0.72, 95% CI 0.48 to 1.07). The risk increased with duration of PPIs use (HR 5.04, 95% CI 1.23 to 20.61; 6.65, 95% CI 1.62 to 27.26 and 8.34, 95% CI 2.02 to 34.41 for ≥1 year, ≥2 years and ≥3 years, respectively). The adjusted absolute risk difference for PPIs versus non-PPIs use was 4.29 excess GC (95% CI 1.25 to 9.54) per 10 000 person-years. CONCLUSION: Long-term use of PPIs was still associated with an increased GC risk in subjects even after HP eradication therapy.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2017. PMID: 29089382. doi:10.1136/gutjnl-2017-314605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。